CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023 08:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Reports First Half 2023 Financial Results
September 07, 2023 17:00 ET
|
Centogene NV
First half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue...
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
August 31, 2023 16:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers...
CENTOGENE to Participate in Upcoming Conferences in August
August 07, 2023 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
July 14, 2023 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort
July 12, 2023 07:30 ET
|
Centogene NV
Inclusion of 602 patients from 47 countries represents the world’s largest and most heterogeneous Niemann-Pick type C1 disease (NPC1) cohortStudy identified 287 unique Pathogenic/Likely Pathogenic...
CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting
June 30, 2023 16:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
June 27, 2023 07:30 ET
|
Centogene NV
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF) based in RiyadhJV...
CENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
June 14, 2023 16:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers...
CENTOGENE Reports Full Year 2022 Financial Results
May 16, 2023 18:25 ET
|
Centogene NV
Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control...